Skip to content

genedrive signs distribution agreement with Beckman Coulter for COVID-19 PCR testing

genedrive plc, the near patient molecular diagnostics company, has announced that it has entered into a distribution agreement with Beckman Coulter Life Sciences (“Beckman Coulter”) for its Genedrive® 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive’s high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory … Continued

Surrey trust pilots the NHS’ first-of-its-kind demand-led rostering solution with Rotageek

Surrey-based Ashford and St Peter’s Hospitals NHS Foundation Trust, one of the UK’s foremost Trusts, is piloting a demand-led rostering solution with Rotageek and Locum’s Nest, who create software connecting healthcare professionals to flexible work. Together they will test the NHS’ first-of-its-kind demand-led rostering. The solution links scheduling and locums in an integrated network that … Continued

An Investment Outlook: Looking forward to 2021

Richard Moore – Co head of Investments 2020 impacted businesses both large and small. Covid-19 and government mandated lockdowns created a very uncertain economic outlook and companies across the board took measures to strengthen balance sheets and preserve cash. The impacts were not felt equally and sectors such as consumer, leisure and retail were hit … Continued

Oxford BioTherapeutics establishes research collaboration with global cell therapy leader, Kite

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies and Kite, a Gilead Company, have announced that they have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five … Continued

Arecor’s partner Inhibrx to license first formulation

Arecor has announced that partner Inhibrx Inc. is to license a novel enhanced formulation of its proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™. This is the first license under a multi-product development agreement between two companies with the new formulation developed using Arestat, Arecor’s patented reformulation platform. INBRX-101 is a treatment for … Continued